- Home
- LXEH vs VIVS Comparison
LXEH vs VIVS Comparison
Compare LXEH & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | VIVS |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 3.8M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LXEH | VIVS |
|---|---|---|
| Price | $1.79 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 310.5K | ★ 572.6K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,603,000.00 |
| Revenue This Year | N/A | $228,144.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.16 | $0.19 |
| 52 Week High | $2.50 | $3.41 |
Technical Indicators
Market Signals| Indicator | LXEH | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 23.04 |
| Support Level | $1.18 | N/A |
| Resistance Level | $2.42 | $0.30 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 35.96 | 3.80 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.